Markets

Biotech Enanta Pharmaceuticals sets terms for $60 million IPO

Enanta Pharmaceuticals, a biotech focused on developing small molecule drugs to use against hepatitis C, announced terms for its IPO on Tuesday. The Watertown, MA-based company plans to raise $60 million by offering 4 million shares at a price range of $14 to $16. At the midpoint of the proposed range, Enanta Pharmaceuticals would command a market value of $253 million.

Enanta Pharmaceuticals, which booked $69 million in sales for the 12 months ended December 31, 2012, plans to list on the NASDAQ under the symbol ENTA. J.P. Morgan and Credit Suisse are the joint bookrunners on the deal.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

ENTA

Other Topics

IPOs

Latest Markets Videos

Renaissance Capital

Renaissance Capital is the global leader in providing pre-IPO institutional research and management of IPO-focused investment products.

Learn More